دورية أكاديمية

FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancer

التفاصيل البيبلوغرافية
العنوان: FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancer
المؤلفون: Sébastien Thureau, Bernard Dubray, Romain Modzelewski, Pierre Bohn, Sébastien Hapdey, Sabine Vincent, Elodie Anger, David Gensanne, Nicolas Pirault, Gouel Pierrick, Pierre Vera
المصدر: Radiation Oncology, Vol 13, Iss 1, Pp 1-7 (2018)
بيانات النشر: BMC, 2018.
سنة النشر: 2018
المجموعة: LCC:Medical physics. Medical radiology. Nuclear medicine
LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
مصطلحات موضوعية: Positron emission tomography, 18fluoro-deoxy-D-glucose, 18fluoro-misonidasole, Lung cancer, Hypoxia, Radiotherapy, Medical physics. Medical radiology. Nuclear medicine, R895-920, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
الوصف: Abstract Background Concomitant chemo-radiotherapy is the reference treatment for non-resectable locally-advanced Non-Small Cell Lung Cancer (NSCLC). Increasing radiotherapy total dose in the whole tumour volume has been shown to be deleterious. Functional imaging with positron emission tomography (PET/CT) offers the potential to identify smaller and biologically meaningful target volumes that could be irradiated with larger doses without compromising Organs At Risk (OAR) tolerance. This study investigated four scenarios, based on 18FDG and 18F-miso PET/CT, to delineate the target volumes and derive radiotherapy plans delivering up to 74Gy. Method Twenty-one NSCLC patients, selected from a prospective phase II trial, had 18FDG- and 18F-miso PET/CT before the start of radiotherapy and 18FDG PET/CT during the radiotherapy (42Gy). The plans were based planned on a standard plan delivering 66 Gy (plan 1) and on three different boost strategies to deliver 74Gy total dose in pre-treatment 18FDG hotspot (70% of SUVmax) (plan 2), pre-treatment 18F-miso target (SUVmax > 1.4) (plan 3) and per-treatment 18FDG residual (40% of SUVmax). (plan 4). Results The mean target volumes were 4.8 cc (± 1.1) for 18FDG hotspot, 38.9 cc (± 14.5) for 18F-miso and 36.0 cc (± 10.1) for per-treatment 18FDG. In standard plan (66 Gy), the mean dose covering 95% of the PTV (D95%) were 66.5 (± 0.33), 66.1 (± 0.32) and 66.1 (± 0.32) Gy for 18FDG hotspot, 18F-miso and per-treatment 18FDG. In scenario 2, the mean D95% was 72.5 (± 0.25) Gy in 18FDG hotspot versus 67.9 (± 0.49) and 67.9 Gy (± 0.52) in 18F-miso and per-treatment 18FDG, respectively. In scenario 3, the mean D95% was 72.2 (± 0.27) Gy to 18F-miso versus 70.4 (± 0.74) and 69.5Gy (± 0.74) for 18FDG hotspot and per-treatment 18FDG, respectively. In scenario 4, the mean D95% was 73.1 (± 0.3) Gy to 18FDG per-treatment versus 71.9 (± 0.61) and 69.8 (± 0.61) Gy for 18FDG hotspot and 18F-miso, respectively. The dose/volume constraints to OARs were matched in all scenarios. Conclusion Escalated doses can be selectively planned in NSCLC target volumes delineated on 18FDG and 18F-miso PET/CT functional images. The most relevant strategy should be investigated in clinical trials. Trial registration (RTEP5, NCT01576796, registered 15 june 2012)
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 1748-717X
Relation: http://link.springer.com/article/10.1186/s13014-018-1147-2; https://doaj.org/toc/1748-717X
DOI: 10.1186/s13014-018-1147-2
URL الوصول: https://doaj.org/article/e7b73cd543cb4d4baf769fcc816df445
رقم الأكسشن: edsdoj.7b73cd543cb4d4baf769fcc816df445
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:1748717X
DOI:10.1186/s13014-018-1147-2